Drugs / CTT1057
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03822871 | Apr 2019 → Oct 2022 | prostate cancer | Cancer Targeted Technology | Completed | No outcome recorded |
| Phase 1 | NCT03427476 | Jan → Aug 2018 | renal cell carcinoma | Cancer Targeted Technology | Completed | No outcome recorded |
| Phase 1 | NCT02916537 | Sep 2016 → Aug 2017 | prostate cancer | Cancer Targeted Technology | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTT1057 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03822871 ↗ |
| Action | Inhibit | “the only known irreversible PSMA inhibitors” NCT03427476 ↗ |
| Modality | Small molecule | “a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA)” NCT02916537 ↗ |
| Route | Intravenous | “will be injected intravenously as a bolus injection.” NCT02916537 ↗ |